KPTI — Karyopharm Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1503802 ·
Last close
$8.97
Market Cap
$203.29M
52W High
$10.23
52W Low
$5.00
ADV30
435,251
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 35,066,000 | 33,721,000 | -26,760,000 | -22,392,000 | 131,417,000 | 90,850,000 | 397,063,000 |
| Dec 2025 | 34,079,000 | 32,595,000 | -17,844,000 | -102,198,000 | 108,416,000 | 60,540,000 | 401,342,000 |
| Sep 2025 | 44,044,000 | 41,931,000 | -15,220,000 | -33,127,000 | 96,232,000 | 37,672,000 | 365,490,000 |
| Jun 2025 | 37,929,000 | 36,878,000 | -24,387,000 | -37,252,000 | 104,879,000 | 38,725,000 | 343,805,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-75,369,000
Investing CF
$43,378,000
Financing CF
$30,372,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.62
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,759,499,000
Inventory
$4,038,000
Receivables
$26,178,000
ST Investments
$3,204,000
EBIT TTM
$-150,147,000
Pretax Income TTM
$-195,996,000
Interest Exp TTM
$45,849,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$151,118,000
EBITDA
$-83,919,000
Free Cash Flow
—
Enterprise Value
$389,835,040
Total Cash
$90,850,000
Total Debt
$296,726,016
Shares Out
22,662,943
Trailing EPS
$-16.38
Book Value
$-16.00
ROE
—
ROA
-40.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 146,067,000 | -90,707,000 | -196,039,000 | 108,416,000 | 401,342,000 | — | -75,369,000 |
| Dec 2024 | 145,237,000 | -119,443,000 | -76,422,000 | 164,418,000 | 350,435,000 | — | -127,486,000 |
| Dec 2023 | 146,033,000 | -129,540,000 | -143,099,000 | 240,438,000 | 376,644,000 | — | -92,723,000 |
| Dec 2022 | 157,074,000 | -142,202,000 | -165,291,000 | 358,172,000 | 374,828,000 | — | -149,554,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | $203.56M | $12.77 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $204.93M | $7.21 | — |
| CAMP | Camp4 Therapeutics Corp | $212.90M | $4.10 | — |
| TLSA | Tiziana Life Sciences Ltd | $192.16M | $1.51 | — |
| NBP | NovaBridge Biosciences | $215.11M | $1.86 | — |
News headlines (Yahoo Finance, 1h cache)
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
2026-05-26 12:04 · Yahoo
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
2026-05-26 11:06 · Yahoo
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
2026-05-25 10:56 · Yahoo
Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
2026-05-14 23:04 · Yahoo
Karyopharm Therapeutics Inc. Q1 2026 Earnings Call Summary
2026-05-14 21:19 · Yahoo
Karyopharm Therapeutics Q1 Earnings Call Highlights
2026-05-14 17:09 · Yahoo
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
2026-05-14 12:45 · Yahoo
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
2026-05-14 11:30 · Yahoo
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
2026-05-12 21:15 · Yahoo
Karyopharm to Participate at Upcoming Investor Conferences
2026-05-12 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.